Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients

J Gastroenterol Hepatol. 2021 Feb;36(2):367-375. doi: 10.1111/jgh.15280. Epub 2020 Oct 11.

Abstract

Background and aim: Since the advent of direct-acting antiviral (DAA) therapy, the total eradication of hepatitis C virus has been achievable with the recovery of hepatic reserve after achievement of sustained virologic response (SVR). Hence, here, we examined the factors affecting the recovery of hepatic reserve.

Methods: We followed up 403 patients (male: 164, female: 239; genotype 1: 299, genotype 2: 104; median age: 69 years) for at least 3 years after they achieved SVR to DAA therapy. Of these patients, 75 (18.6%) had a history of hepatocellular carcinoma (HCC). Biochemical tests were periodically performed, and the hepatic reserve was evaluated based on the albumin-bilirubin grade. We examined background factors such as age, biochemical test results, HCC occurrence and portosystemic shunt by computed tomography.

Results: At the start of treatment, the albumin-bilirubin grades were grades 1, 2, and 3 in 241, 157, and 5 patients, respectively, and 3 years later, 117 of 162 (72%) patients with grade 2 or 3 improved to grade 1. Multivariate analysis identified the HCC occurrence after achievement of SVR (hazard ratio [HR]: 3.08, P < 0.0138), male sex (HR: 3.45, P = 0.0143), hemoglobin level of <11.5 g/dL (HR: 4.19, P = 0.0157), the presence of a portosystemic shunt (HR: 3.07, P = 0.0349), and alanine aminotransferase levels <45 U/L (HR: 2.67, P = 0.0425) as factors inhibiting improvement to grade 1. However, old age was not an inhibitory factor.

Conclusion: Our results demonstrate that hepatic reserve could be improved even in elderly patients over a long course of time.

Keywords: ALBI score; Age; Child-Pugh classification; Direct acting antivirals; Hepatic reserve; Hepatitis C; Sustained virologic response.

MeSH terms

  • Aged
  • Alanine Transaminase
  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / epidemiology
  • Carcinoma, Hepatocellular / etiology
  • Female
  • Hepacivirus
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / physiopathology
  • Hepatitis C, Chronic / virology*
  • Humans
  • Liver / physiopathology*
  • Liver Function Tests
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / etiology
  • Male
  • Middle Aged
  • Recovery of Function*
  • Sex Factors
  • Sustained Virologic Response*

Substances

  • Antiviral Agents
  • Alanine Transaminase